Smith & Nephew Snats ((SNN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Smith & Nephew Snats is conducting a clinical study titled ‘A Clinical Evaluation of a New NPWT Dressing’ to assess the effectiveness of a new Negative Pressure Wound Therapy (NPWT) dressing in treating chronic and acute wounds. This study aims to provide insights into the dressing’s clinical performance, potentially offering a significant advancement in wound care management.
The intervention being tested is the RENASYS Film with AIRLOCK Technology, a device designed for use with Smith+Nephew RENASYS NPWT Systems. It is intended to enhance the management of chronic and acute wounds through innovative technology.
The study is observational in nature, focusing on patients with chronic and acute wounds. It employs a case-only observational model with a prospective time perspective, meaning it will follow patients over time to observe outcomes.
The study began on February 29, 2024, with the latest update submitted on September 22, 2025. These dates are crucial as they mark the study’s progress and the most recent developments in its findings.
This clinical study update could influence Smith & Nephew’s stock performance positively, as successful results may enhance their market position in wound care. Investors should watch for competitor responses and industry shifts as the study progresses.
The study is currently ongoing, with further details available on the ClinicalTrials portal.